Activities of Bart STAES related to 2012/2041(INI)
Shadow reports (1)
REPORT on the Microbial Challenge – Rising threats from Antimicrobial Resistance PDF (224 KB) DOC (156 KB)
Amendments (17)
Amendment 5 #
Motion for a resolution
Recital A
Recital A
A. whereas the development of drug resistance is a natural and unavoidable consequence of antimicrobial treatment; whereas this process can beis accelerated by inordinate and indiscriminate use in human and veterinary medicine, which, combined with insufficient hygiene and infection control, can as well as high-density animal husbandry, compromises the effective use of an already limited number of existing antimicrobials;
Amendment 11 #
Motion for a resolution
Recital D
Recital D
D. whereas the rise of antimicrobial resistance (AMR) is a complex issue driven by a variety of interconnected factors; whereas individual intervention measures will have minimal effectnumerous intervention measures at various levels are necessary, as isolated intervention measures will have only limited effect; whereas the pending revision of the veterinary legislation is an important opportunity to take effective measures to reduce AMR;
Amendment 18 #
Motion for a resolution
Recital G
Recital G
G. whereas there is a clear link between antimicrobials use in animals and the spread of resistance in humans, which requires further research; whe: high- density livestock is far more at risk of infections, and infections therein spread faster; high-density farming thus often relies on systematic prophylactic or sub- therapeutic use of antimicrobials to protect livestock from infections, which significantly increases there is a need for a coordinated, multisectoral policy approach to AMR targeting both practitioners and users in each sector risk of developing AMR; a significant percentage of meat for human consumption from high-density farming, in particular turkey and chicken meat, is regularly found to be contaminated with microbes that are resistant to antimicrobials; these resistances can be transferred to beneficial microbes in the human body upon human contact with the raw meat, which can lead to AMR in humans; while further research would be useful, enough is known to tackle unsustainable farming practices in a coordinated, multisectoral policy approach;
Amendment 30 #
Motion for a resolution
Paragraph -1 (new)
Paragraph -1 (new)
-1. Notes that, although the Commission's action plan goes in the right direction, it does not go far enough to contain the rising threat from antimicrobial resistance;
Amendment 38 #
Motion for a resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls on the Commission to propose clear obligations on Member States to effectively control the prudent use of antimicrobials in human and veterinary medicine, and to report about these controls;
Amendment 43 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Stresses that more efforts are needed to control the use of antimicrobials in the veterinary sector; strongly disapproves of the uncontrolled prophylacprophylactic or sub-therapeutic use of antimicrobials in animal husbandry;
Amendment 48 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Calls on the Commission to draw up legislative proposals to reduce the maximum animal density in livestock farming to a level that respects animal welfare and is sustainable, not least to reduce the risk of infections and disease transmission;
Amendment 50 #
Motion for a resolution
Paragraph 3 b (new)
Paragraph 3 b (new)
3b. Calls on the Commission to strengthen the provisions for the authorization of veterinary medicines in the upcoming revision with a view to reducing AMR;
Amendment 52 #
Motion for a resolution
Paragraph 3 c (new)
Paragraph 3 c (new)
3c. Calls on the Member States to phase out the prophylactic, metaphylactic and sub-therapeutic use of antimicrobials in livestock farming in national legislation and instead establish in a legally binding manner good practices for animal husbandry that prevent infections and thus reduce the risk of AMR, limiting antimicrobial use to effective treatment of infected animals only, as guidelines on prudent use have been unable to resolve the problem;
Amendment 54 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls further on the Commission to come up with a legislative proposal for the veterinary sector to limit the use of third- and fourth-generation CIAs forto humans; stresses that any such proposal must be founded on evidence-based European guidelines on the prudent use of antimicrobials in veterinary medicine only;
Amendment 72 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Notes the important role of vaccines in limiting the development of AMR by reducing the amounts of antimicrobial agents required to treat infections but considers that this must not be a substitute for good animal husbandry;
Amendment 78 #
Motion for a resolution
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Calls for a legally binding obligation to reduce the antimicrobial use in animal husbandry in the EU by at least 50% by 2018, compared to 2012 figures, for each class of antimicrobials;
Amendment 86 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Calls on the Commission and the Member States, after having taken decisive action to minimize the unnecessary use of antimicrobials, to encourage efforts to develop new and innovative public-private partnership (PPP) business models that delink investment in R&D for new antibiotics and diagnostic tools from sales transactions, in order to promote greater access and affordability and limit the unnecessary use of antimicrobials;
Amendment 89 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Highlights the need to be restrictive with the use of CIAs andto the use in humans only and to be restrictive in the use of newly developed antimicrobial agents and technologies for use in human and veterinary medicine; stresses the importance of appropriately targeting the use of CIAs to specific casescases where their use is strictly necessary;
Amendment 90 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Calls on the Commission and the Member States to examine new regulatory approaches, including transferable intellectual property rights and patent term extensionrize funds, with a view to encouraging private-sector investment in antimicrobial development;
Amendment 102 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Stresses the importance of establishing an effective European network of national surveillance systems in the human health and veterinary sectors in order to facilitatensure the compilation of clear, comparable, transparent and timely reference data on antimicrobial drug usage; believes this should be based on the existing monitoring networks operated by EFSA, the ECDC European Surveillance of Antimicrobial Consumption Network (ESAC-net), the ECDC European Antimicrobial Resistance Surveillance Network (EARS-net), and the EMA European Surveillance of Veterinary Antimicrobial Consumption (ESVAC);
Amendment 107 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Calls on the Commission in the context of the upcoming review of the legislation on veterinary medicines to propose clear reporting obligations on all pharmaceutical companies, veterinarians and farmers, respectively, about the amount of antimicrobials that they sell, prescribe and use, respectively;